Effects of denosumab on fracture and bone mineral density by level of kidney function

The incidences of osteoporosis and chronic kidney disease (CKD) both increase with increasing age, yet there is a paucity of data on treatments for osteoporosis in the setting of impaired kidney function. We examined the efficacy and safety of denosumab (DMAb) among subjects participating in the Fra...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of bone and mineral research 2011-08, Vol.26 (8), p.1829-1835
Main Authors:	Jamal, Sophie A, Ljunggren, Östen, Stehman‐Breen, Catherine, Cummings, Steven Ron, McClung, Michael R, Goemaere, Stefan, Ebeling, Peter R, Franek, Edward, Yang, Yu‐ching, Egbuna, Ogo I, Boonen, Steven, Miller, Paul D
Format:	Article
Language:	English
Subjects:	Aged Aged, 80 and over Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Biological and medical sciences Bone Density - drug effects Bone Density - physiology Bone Density Conservation Agents - adverse effects Bone Density Conservation Agents - pharmacology Bone Density Conservation Agents - therapeutic use BONE MINERAL DENSITY Creatinine - blood DENOSUMAB Female FRACTURES Fractures, Bone - blood Fractures, Bone - drug therapy Fractures, Bone - physiopathology Fundamental and applied biological sciences. Psychology Glomerular Filtration Rate Humans IMPAIRED KIDNEY FUNCTION Kidney Failure, Chronic - blood Kidney Failure, Chronic - complications Kidney Failure, Chronic - physiopathology Kidney Function Tests MEDICIN MEDICINE Middle Aged Odds Ratio Placebos RANK Ligand - adverse effects RANK Ligand - pharmacology RANK Ligand - therapeutic use Skeleton and joints Vertebrates: osteoarticular system, musculoskeletal system
Citations:	Items that this one cites Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!